Skip to content
StockMarketAgent
Direct answer
ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $411, high $854, with mid-point at $632.
Stock analysis

ELV ELV fair value $411–$854

ELV
By StockMarketAgent.AI team· supervised by
Đã phân tích: 2026-05-13Cập nhật tiếp theo: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Giá
$381.75
▲ +250.57 (+65.64%)
Giá trị hợp lý
$632
$411–$854
Khuyến nghị
Mua mạnh
confidence 77/100
Tiềm năng tăng
+65.6%
upside to fair value
Biên an toàn
$537.47
MoS level · 15%
Vốn hóa thị trường
$82.9B
P/E fwd 13.1
Dự phòng tiếng AnhVI
Hiển thị bản gốc tiếng Anh trong khi đang dịch
Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.

§1 Tóm tắt điều hành

  • Composite fair value $632 with high case $854.
  • Implied upside of 65.6% to fair value.
  • Moat 9/10 · confidence 77/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$632
Margin of safety
+39.6%
Confidence
77/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$381.75Price
Low $411.38
Mid $632.32
High $853.64

ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Scale advantages driven by a
    Scale advantages driven by a massive member base in Anthem.
  • Network effects within the integrated
    Network effects within the integrated Anthem and Carelon ecosystems.
  • Bull thesis
    Massive margin of safety with implied -6.18% perpetual growth at the current price.

§2 Kịch bản tiêu cực

A severe scenario where elevated MLR persists due to structural shifts in medical utilization, compounded by adverse Medicare rate changes, significantly compressing operating margins below their historical norms.

Các cách luận điểm này có thể đổ vỡ

Unchecked Medical Cost Inflation

· Medium

Sustained elevated medical utilization drives MLR structurally higher, compressing operating margins permanently below historical averages.

FV impact
-35%
Trigger
12-24 Months

Severe Regulatory Reimbursement Cuts

· Low

Aggressive legislative action slashes Medicare Advantage and Medicaid reimbursement rates, effectively stunting top-line growth.

FV impact
-25%
Trigger
24-36 Months

Carelon Growth Stagnation

· Medium

Intense PBM competition limits Carelon's ability to win new external mandates, stalling the long-term margin-expansion thesis.

FV impact
-15%
Trigger
12-18 Months
Tín hiệu cảnh báo sớm cần theo dõi
Chỉ sốHiện tạiNgưỡng kích hoạt
Medical loss ratio sequentially rising above targeted corridors.MonitorDeterioration versus the report thesis
Regulatory announcements of tighter Medicare funding.MonitorDeterioration versus the report thesis
Stalling growth or mandate losses in the Carelon segment.MonitorDeterioration versus the report thesis
Operating margins dipping below the 5.0% normalized threshold.MonitorDeterioration versus the report thesis
Material reduction in projected share repurchase pacing.MonitorDeterioration versus the report thesis

§3 Lịch sử tài chính

Báo cáo kết quả kinh doanh — sáu kỳ gần nhất
Khoản mụcT−0T−1T−2T−3T−4CAGR
Kỳ2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Doanh thu$156.60B$171.34B$176.81B$199.13B+6.2%
Lợi nhuận gộp
Lợi nhuận hoạt động
Lợi nhuận ròng$5.89B$5.99B$5.98B$5.66B-1.0%
EPS (pha loãng)$24.81$25.22$25.68$25.21+0.4%
EBITDA
R&D
SG&A$15.91B$17.69B+2.7%

Điểm chất lượng

OCF / Lợi nhuận ròng
0.76×
>1 cho thấy chất lượng lợi nhuận cao
Cổng chất lượng kế toán
Fail
Cổng điều chỉnh theo ngành
ROIC
8.4%
Tỷ suất sinh lời trên vốn đầu tư
Phần 3

Numbers analysis

Dòng tiền

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Phân bổ vốn

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Người đăng ký cá nhân — từ §411 phần nữa

Đọc phân tích đầy đủ — 11 phần nữa.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Báo cáo đầy đủ cho mọi mã được phủ
Lưu trữ khuyến nghị 24 tháng
Bản tin watchlist + cảnh báo thay đổi khuyến nghị
Xuất PDF + DOCX bằng mọi ngôn ngữ
Bắt đầu dùng thử miễn phí
Hủy bất kỳ lúc nào.
FAQ

ELV — frequently asked questions

  1. Based on our latest analysis, ELV looks meaningfully undervalued. The current price is $382 versus a composite fair-value midpoint of $632 (range $411–$854), which implies roughly 65.6% upside to the midpoint.
Related coverage

Names readers of ELV also follow

Same archetype: mature-compounder